Moreover, there are some common serum tumor FDA approved biomarkers for screening high-risk OC women, including carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), human epididymis protein 4 (HE4), risk of ovarian malignancy algorithm (ROMA), ova1, and overa [5]. This evidence concerns the gene CEACAM5 and neoplasm.